Yıl: 2018 Cilt: 46 Sayı: 8 Sayfa Aralığı: 723 - 734 Metin Dili: Türkçe DOI: 10.5543/tkda.2018.37048 İndeks Tarihi: 17-08-2020

Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü

Öz:
-
Anahtar Kelime:

Vaccination of adults with heart failure and chronic heart conditions: Expert opinion

Öz:
-
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1. Cardiovascular diseases (CVDs). World Health Organization. Fact sheet. May 2017. Available at: http://www.who. int/mediacentre/factsheets/fs317/en/index.html. Accessed Oct 31, 2018.
  • 2. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasivepneumococcal disease. Thorax 2015;70:984–9.
  • 3. Mor A, Thomsen RW, Ulrichsen SP, Sørensen HT. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med 2013;24:349–53.
  • 4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumoniaamong adults in Europe. Thorax 2012;67:71–9.
  • 5. Lode HM. Managing community-acquired pneumonia: a European perspective. Respir Med 2007;101:1864–73.
  • 6. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization. Available at: https://www. who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed Oct 31, 2018.
  • 7. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013;68:1057–65.
  • 8. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al; Asian Network for Surveillanceof Resistant Pathogens Study Group. Epidemiology and clinical outcomes of community-acquired pneumoniain adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008;31:107–14.
  • 9. Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, et al; SIXTUS Study Group. Platelet activation is associated with myocardial infarction in patientswith pneumonia. J Am Coll Cardiol 2014;64:1917–25.
  • 10. Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S, Cameron DW, et al. Cardiac complications in patients with community-acquiredpneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011;8:e1001048.
  • 11. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquiredpneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773–81.
  • 12. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013;381:496–505.
  • 13. Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. Respirology 2018;23:250–9.
  • 14. Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Risk of heart failure after community acquired pneumonia: prospectivecontrolled study with 10 years of follow-up. BMJ 2017;356:j413.
  • 15. Bergh C, Fall K, Udumyan R, Sjöqvist H, Fröbert O, Montgomery S. Severe infections and subsequent delayed cardiovascular disease. Eur J Prev Cardiol 2017;24:1958–66.
  • 16. Akçakaya N, Camcıoğlu Y, Gür E, Öztürk R. Çocuk ve erişkinlerde aşılama. İÜ Cerrahpaşa Tıp Fak Sürekli Tıp Eğitimi Etkinlikleri. No:71. İstanbul: 2010. Available at: http://www.ctf.edu.tr/stek/pdfs/71/7101.pdf. Accessed Oct 31, 2018.
  • 17. Ünal S. Çalışma hayatında yetişkin aşılamanın yeri ve önemi. Çalışma Hayatında Bulaşıcı Hastalıklar Sempozyumu. Ankara: Feb 2013. Available at: http://www.hisam.hacettepe. edu.tr/chbhastalik/sunum/SerhatUnalII.pdf. Accessed Oct 31, 2018.
  • 18. Alici DE, Sayiner A, Unal S. Barriers to adult immunization and solutions: Personalized approaches. Hum Vaccin Immunother 2017;13:213–5.
  • 19. Sessa A, Rossi A, Cricelli I. Adult immunization schedule. The general practitioner’s perspectiveand new tools for a better practice. J Prev Med Hyg 2015;56:E9–11.
  • 20. Şenol E. Erişkin Aşılaması. 13. Ulusal Çocuk Enfeksiyon Hastalıkları Sempozyumu. Eskişehir: 2016.
  • 21. Lipsitch M, Siber GR. How Can Vaccines Contribute to Solving the Antimicrobial ResistanceProblem? MBio 2016;7. pii: e00428–16.
  • 22. Aliberti S, Ramirez JA. Cardiac diseases complicating community-acquired pneumonia. Curr Opin Infect Dis 2014;27:295–301.
  • 23. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiacevents. Clin Infect Dis 2007;45:158–65.
  • 24. Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis 2013;56:1145–6.
  • 25. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114–25.
  • 26. Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertoncello C, et al. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian RegionalExperience. PLoS One 2016;11:e0166637.
  • 27. Altun HU, Hascelik G, Gür D, Eser ÖK. Invasive pneumococci before the introduction of pneumococcalconjugate vaccine in Turkey: antimicrobial susceptibility, serotypedistribution, and molecular identification of macrolide resistance. J Chemother 2015;27:74–9.
  • 28. Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, currentvaccination status, factors influencing vaccine uptake and steps takento increase vaccination rate. Vaccine 2013;31:518–23.
  • 29. Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol 2013;167:2397–403.
  • 30. Kadoglou NPE, Bracke F, Simmers T, Tsiodras S, Parissis J. Influenza infection and heart failure-vaccination may change heartfailure prognosis? Heart Fail Rev 2017;22:329–36.
  • 31. Bhatt AS, DeVore AD, Hernandez AF, Mentz RJ. Can Vaccinations Improve Heart Failure Outcomes?: ContemporaryData and Future Directions. JACC Heart Fail 2017;5:194–203.
  • 32. Kaya H, Beton O, Acar G, Temizhan A, Cavusoğlu Y, Guray U, et al; TREAT-HF Investigators. Influence of influenza vaccination on recurrent hospitalization in patients with heart failure. Herz 2017;42:307–15.
  • 33. de Diego C, Vila-Córcoles A, Ochoa O, Rodriguez-Blanco T, Salsench E, Hospital I, et al; EPIVAC Study Group. Effects of annual influenza vaccination on winter mortality in elderlypeople with chronic heart disease. Eur Heart J 2009;30:209–16.
  • 34. Blaya-Nováková V, Prado-Galbarro FJ, Sarría-Santamera A. Effects of annual influenza vaccination on mortality in patients with heart failure. Eur J Public Health 2016;26:890–2.
  • 35. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, et al; PARADIGM-HF Investigators. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail 2016;4:152–8.
  • 36. Özsu S, Uçar E, Arslan Y, Maden E, Bilgiç H. The Frequency of Influenza and Pneumococcal Vaccination in COPD. Solunum 2011;13:21–5.
  • 37. Erer OF, Karadeniz G, Gazibaba D, Ürpek G, Yalnız E, Aktoğu SÖ. Immunization in the chronic obstructive pulmonary disease: can we have really done it? İzmir Göğüs Hastanesi Dergisi 2013;27:31–40.
  • 38. Satman I, Akalin S, Cakir B, Altinel S; diaVAX Study Group. The effect of physicians’ awareness on influenza and pneumococcalvaccination rates and correlates of vaccination in patients with diabetes in Turkey: an epidemiological Study “diaVAX”. Hum Vaccin Immunother 2013;9:2618–26.
  • 39. “10 Keys”™ to Healthy Aging Work book and the Instructor Manual. Mar 3, 2018. Available at: http://www12.edc. gsph.pitt.edu/CHA_OAEP/Documents/ParticipantWorkbook2016.pdf. Accessed Apr 2018.
  • 40. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018. Feb 6, 2018. Centers for Disease Control and Prevention. Available at: https://www. cdc.gov/vaccines/schedules/hcp/imz/adult-compliant.html. Accessed Nov 1, 2018.
  • 41. Cafiero-Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. The full benefits of adult pneumococcal vaccination: A systematic review. PLoS One 2017;12:e0186903.
  • 42. Tan LLJ. A review of the key factors to improve adult immunization coverage rates: What can the clinician do? Vaccine 2018;36:5373–8.
  • 43. Ünal S. Erişkin Aşılama Programları, Oranlar? 6. Ulusal Aşı Sempozyumu. Ankara: 2015.
  • 44. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481–8.
  • 45. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001;11:142– 7.
  • 46. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988– 98.
  • 47. Thomsen RW, Kasatpibal N, Riis A, Nørgaard M, Sørensen HT. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J Gen Intern Med 2008;23:1407–13.
  • 48. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005;353:2788–96.
  • 49. Koivula I, Sten M, Mäkelä PH. Risk factors for pneumonia in the elderly. Am J Med 1994;96:313–20.
  • 50. Klare B, Kubini R, Ewig S. Risk factors for pneumonia in patients with cardiovascular diseases. [Article in German]. Pneumologie 2002;56:781–8.
  • 51. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medicalconditions. Open Forum Infect Dis 2014;1:ofu024.
  • 52. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and CongenitalCardiology (AEPC), International Society for Heart and LungTransplantation (ISHLT). Eur Heart J 2016;37:67–119.
  • 53. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Preventionin Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation(EACPR). Eur Heart J 2016;37:2315–81.
  • 54. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatmentof acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the HeartFailure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
  • 55. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the WorldHeart Federation and the Preventive Cardiovascular NursesAssociation. J Am Coll Cardiol 2011;58:2432–46.
  • 56. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practiceguidelines. Circulation 2013;128:1810–52.
  • 57. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With ValvularHeart Disease: a report of the American College of Cardiology/American Heart Association Task Force on PracticeGuidelines. Circulation 2014;129:e521–643.
  • 58. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al; Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:e1–194
  • 59. Kim DK, Riley LE, Hunter P; Advisory Committee on Immunization Practices. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018. Ann Intern Med 2018;168:210–20.
  • 60. Taylan M. Pnömokok Aşıları. Güncel Göğüs Hastalıkları Serisi 2014;2:98–105.
  • 61. Risk Grubu Aşılamaları. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu. Mayıs 27,2016. Sayı: 21001706/131.99.
  • 62. EKMUD. Erişkin Bağışıklama Rehberi. Türkiye Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Uzmanlık Derneği, Erişkin Bağışıklama Rehberi Çalışma Grubu. 2. Güncelleme, Mayıs 2016. Available at: http://ekmud.org.tr/calisma-grubu/ 4-bagisiklama-calisma-grubu. Accessed Nov 1, 2018.
  • 63. Şenol E, Azap A, Erbay A, Alp Çavuş S, Karakuş R, Acar A. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases. Klimik Dergisi 2018;31:2–18.
  • 64. Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthyadults. Clin Vaccine Immunol 2012;19:1296–303.
APA ÇELİK A, Altay H, AZAP A, Çavuşoğlu Y, Nalbantgil S, ŞENOL E, Temizhan A, YILMAZ M (2018). Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. , 723 - 734. 10.5543/tkda.2018.37048
Chicago ÇELİK Ahmet,Altay Hakan,AZAP Alpay,Çavuşoğlu Yüksel,Nalbantgil Sanem,ŞENOL ESİN,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. (2018): 723 - 734. 10.5543/tkda.2018.37048
MLA ÇELİK Ahmet,Altay Hakan,AZAP Alpay,Çavuşoğlu Yüksel,Nalbantgil Sanem,ŞENOL ESİN,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. , 2018, ss.723 - 734. 10.5543/tkda.2018.37048
AMA ÇELİK A,Altay H,AZAP A,Çavuşoğlu Y,Nalbantgil S,ŞENOL E,Temizhan A,YILMAZ M Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. . 2018; 723 - 734. 10.5543/tkda.2018.37048
Vancouver ÇELİK A,Altay H,AZAP A,Çavuşoğlu Y,Nalbantgil S,ŞENOL E,Temizhan A,YILMAZ M Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. . 2018; 723 - 734. 10.5543/tkda.2018.37048
IEEE ÇELİK A,Altay H,AZAP A,Çavuşoğlu Y,Nalbantgil S,ŞENOL E,Temizhan A,YILMAZ M "Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü." , ss.723 - 734, 2018. 10.5543/tkda.2018.37048
ISNAD ÇELİK, Ahmet vd. "Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü". (2018), 723-734. https://doi.org/10.5543/tkda.2018.37048
APA ÇELİK A, Altay H, AZAP A, Çavuşoğlu Y, Nalbantgil S, ŞENOL E, Temizhan A, YILMAZ M (2018). Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. Türk Kardiyoloji Derneği Arşivi, 46(8), 723 - 734. 10.5543/tkda.2018.37048
Chicago ÇELİK Ahmet,Altay Hakan,AZAP Alpay,Çavuşoğlu Yüksel,Nalbantgil Sanem,ŞENOL ESİN,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. Türk Kardiyoloji Derneği Arşivi 46, no.8 (2018): 723 - 734. 10.5543/tkda.2018.37048
MLA ÇELİK Ahmet,Altay Hakan,AZAP Alpay,Çavuşoğlu Yüksel,Nalbantgil Sanem,ŞENOL ESİN,Temizhan Ahmet,YILMAZ MEHMET BIRHAN Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. Türk Kardiyoloji Derneği Arşivi, vol.46, no.8, 2018, ss.723 - 734. 10.5543/tkda.2018.37048
AMA ÇELİK A,Altay H,AZAP A,Çavuşoğlu Y,Nalbantgil S,ŞENOL E,Temizhan A,YILMAZ M Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. Türk Kardiyoloji Derneği Arşivi. 2018; 46(8): 723 - 734. 10.5543/tkda.2018.37048
Vancouver ÇELİK A,Altay H,AZAP A,Çavuşoğlu Y,Nalbantgil S,ŞENOL E,Temizhan A,YILMAZ M Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü. Türk Kardiyoloji Derneği Arşivi. 2018; 46(8): 723 - 734. 10.5543/tkda.2018.37048
IEEE ÇELİK A,Altay H,AZAP A,Çavuşoğlu Y,Nalbantgil S,ŞENOL E,Temizhan A,YILMAZ M "Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü." Türk Kardiyoloji Derneği Arşivi, 46, ss.723 - 734, 2018. 10.5543/tkda.2018.37048
ISNAD ÇELİK, Ahmet vd. "Kalp yetersizliği ve kronik kalp hastalıklarında erişkin aşılama: Uzman görüşü". Türk Kardiyoloji Derneği Arşivi 46/8 (2018), 723-734. https://doi.org/10.5543/tkda.2018.37048